nach oben

Current Diabetes Reports

Erschienen in:

01.06.2022 | Psychosocial Aspects (J Pierce, Section Editor)

The Use of Diabetes Technology to Address Inequity in Health Outcomes: Limitations and Opportunities

verfasst von: Shivani Agarwal, Iman Simmonds, Alyson K. Myers

Erschienen in: Current Diabetes Reports | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The management of diabetes has been revolutionized by the introduction of novel technological treatments and modalities of care, such as continuous glucose monitoring, insulin pump therapy, and telehealth. While these technologies have demonstrated improvement in health outcomes, it remains unclear whether they have reduced inequities from racial/ethnic minority or socioeconomic status. We review the current literature to discuss evidence of benefit, current limitations, and future opportunities of diabetes technologies.

Findings

While there is ample evidence of the health and psychological benefit of diabetes technologies in large populations of people with type 1 and type 2 diabetes, there remain wide disparities in the use of diabetes technologies, which may be perpetuating or widening inequities. Multilevel barriers include inequitable prescribing practices, lack of support for social determinants of health, mismatch of patient preferences and care models, and cost.

Summary

We provide a review of disparities in diabetes technology use, possible root causes of continued inequity in outcomes, and insight into ways to overcome remaining gaps.

National Diabetes Statistics Report 2020. Estimates of diabetes and its burden in the United States. Published online 2020:32

Only 1 in 4 Adults with diagnosed diabetes achieve combined diabetes care goals | Diabetes | CDC. Published November 13, 2020. Accessed September 28, 2021. https://www.cdc.gov/diabetes/research/reports/diabetes-abcs.html

Foster NC, Beck RW, Miller KM, et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016–2018. Diabetes Technol Ther. 2019;21(2):66–72. https://doi.org/10.1089/dia.2018.0384.CrossRefPubMedPubMedCentral

Addressing health disparities in diabetes | Diabetes | CDC. Published August 11, 2021. Accessed November 15, 2021. https://www.cdc.gov/diabetes/disparities.html

Association AD. Economic costs of diabetes in the U.S. In 2017. Diabetes Care. 2018;41(5):917–28. https://doi.org/10.2337/dci18-0007.CrossRef

Nathan DM, Group for the DR. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37(1):9–16. https://doi.org/10.2337/dc13-2112

Chamberlain JJ, Rhinehart AS, Shaefer CF, Neuman A. Diagnosis and management of diabetes: synopsis of the 2016 American diabetes association standards of medical care in diabetes. Ann Intern Med. 2016;164(8):542–52. https://doi.org/10.7326/M15-3016.CrossRefPubMed

Lai CW, Lipman TH, Willi SM, Hawkes CP. Racial and ethnic disparities in rates of continuous glucose monitor initiation and continued use in children with type 1 diabetes. Diabetes Care. 2021;44(1):255–7. https://doi.org/10.2337/dc20-1663.CrossRefPubMed

Agarwal S, Schechter C, Gonzalez J, Long JA. Racial-ethnic disparities in diabetes technology use among young adults with type 1 diabetes. Diabetes Technol Ther. 2021;23(4):306–13. https://doi.org/10.1089/dia.2020.0338.CrossRefPubMedPubMedCentral

10.

Addala A, Auzanneau M, Miller K, et al. A decade of disparities in diabetes technology use and HbA1c in pediatric type 1 diabetes: a transatlantic comparison. Diabetes Care. 2021;44(1):133–40. https://doi.org/10.2337/dc20-0257.CrossRefPubMed

11.

Addala A, Hanes S, Naranjo D, Maahs DM, Hood KK. Provider implicit bias impacts pediatric type 1 diabetes technology recommendations in the united states: findings from the gatekeeper study. J Diabetes Sci Technol. 2021;15(5):1027–33. https://doi.org/10.1177/19322968211006476.CrossRefPubMedPubMedCentral

12.

Golden SH, Joseph JJ, Hill-Briggs F. Casting a health equity lens on endocrinology and diabetes. J Clin Endocrinol Metab. 2021;106(4):e1909–16. https://doi.org/10.1210/clinem/dgaa938.CrossRefPubMed

13.

Dang YH, Patel-Shori NM, Barros M, Yu D. Good literacy to enhance response in diabetes mellitus (GLITTER-DM). Innov Pharm. 2020;11(3):https://doi.org/10.24926/iip.v11i3.2406

14.

Schillinger D, Grumbach K, Piette J, et al. Association of health literacy with diabetes outcomes. JAMA. 2002;288(4):475–82. https://doi.org/10.1001/jama.288.4.475.CrossRefPubMed

15.

Agarwal S, Crespo-Ramos G, Long JA, Miller VA. “I didn’t really have a choice”: qualitative analysis of racial-ethnic disparities in diabetes technology use among young adults with type 1 diabetes. Diabetes Technol Ther. 2021;23(9):616–22. https://doi.org/10.1089/dia.2021.0075.CrossRefPubMed

16.

Wong JC, Foster NC, Maahs DM, et al. Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry. Diabetes Care. 2014;37(10):2702–9. https://doi.org/10.2337/dc14-0303.CrossRefPubMedPubMedCentral

17.

Tong T, Myers AK, Bissoonauth AA, Pekmezaris R, Kozikowski A. Identifying the barriers and perceptions of non-Hispanic black and Hispanic/Latino persons with uncontrolled type 2 diabetes for participation in a home Telemonitoring feasibility study: a quantitative analysis of those who declined participation, withdrew or were non-adherent. Ethn Health. 2020;25(4):485–94. https://doi.org/10.1080/13557858.2019.1566520.CrossRefPubMed

18.

Isaacs D, Bellini NJ, Biba U, Cai A, Close KL. Health care disparities in use of continuous glucose monitoring. Diabetes Technol Ther. 2021;23(S3):S81–7. https://doi.org/10.1089/dia.2021.0268.CrossRefPubMed

19.

Association AD. 7. Diabetes technology: standards of medical care in diabetes—2021. Diabetes Care. 2021;44(Supplement 1):S85-S99. https://doi.org/10.2337/dc21-S007

20.

Grunberger G, Handelsman Y, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College Of Endocrinology 2018 position statement on integration of insulin pumps and continuous glucose monitoring in patients with diabetes mellitus. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2018;24(3):302–8. https://doi.org/10.4158/PS-2017-0155.CrossRef

21.

Maiorino MI, Signoriello S, Maio A, et al. Effects of continuous glucose monitoring on metrics of glycemic control in diabetes: a systematic review with meta-analysis of randomized controlled trials. Diabetes Care. 2020;43(5):1146–56. https://doi.org/10.2337/dc19-1459.CrossRefPubMed

22.

Miller KM, Beck RW, Foster NC, Maahs DM. HbA1c levels in type 1 diabetes from early childhood to older adults: a deeper dive into the influence of technology and socioeconomic status on HbA1c in the T1D exchange clinic registry findings. Diabetes Technol Ther. 2020;22(9):645–50. https://doi.org/10.1089/dia.2019.0393.CrossRefPubMedPubMedCentral

23.

Walker AF, Hood KK, Gurka MJ, et al. Barriers to technology use and endocrinology care for underserved communities with type 1 diabetes. Diabetes Care. Published online May 17, 2021:dc202753. https://doi.org/10.2337/dc20-2753

24.

Anderson JE, Gavin JR, Kruger DF. Current eligibility requirements for CGM coverage Are harmful, costly, and unjustified. Diabetes Technol Ther. 2020;22(3):169–73. https://doi.org/10.1089/dia.2019.0303.CrossRefPubMedPubMedCentral

25.

Wan W, Skandari MR, Minc A, et al. Cost-effectiveness of continuous glucose monitoring for adults with type 1 diabetes compared with self-monitoring of blood glucose: the DIAMOND randomized trial. Diabetes Care. 2018;41(6):1227–34. https://doi.org/10.2337/dc17-1821.CrossRefPubMedPubMedCentral

26.

Cameron C, Coyle D, Ur E, Klarenbach S. Cost-effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin. CMAJ Can Med Assoc J. 2010;182(1):28–34. https://doi.org/10.1503/cmaj.090765.CrossRef

27.

Alotaibi A, Al Khalifah R, McAssey K. The efficacy and safety of insulin pump therapy with predictive low glucose suspend feature in decreasing hypoglycemia in children with type 1 diabetes mellitus: a systematic review and meta-analysis. Pediatr Diabetes. 2020;21(7):1256–67. https://doi.org/10.1111/pedi.13088.CrossRefPubMed

28.

Janez A, Battelino T, Klupa T, Kocsis G, Kuricová M, Lalić N, Stoian AP, Prázný M, Rahelić D, Šoupal J, Tankova T, Zelinska N. Panel urges expanded technology access for people with type 1 diabetes. Accessed November 24, 2021. https://www.univadis.com/viewarticle/panel-urges-expanded-technology-access-for-people-with-type-1-diabetes-4fceb6a6-1eb6-38ca-8d88-f546ec0d3e89

29.

Hussain T, Akle M, Nagelkerke N, Deeb A. Comparative study on treatment satisfaction and health perception in children and adolescents with type 1 diabetes mellitus on multiple daily injection of insulin, insulin pump and sensor-augmented pump therapy. SAGE Open Med. 2017;5:2050312117694938. https://doi.org/10.1177/2050312117694938.CrossRefPubMedPubMedCentral

30.

Bailey TS, Stone JY. A novel pen-based Bluetooth-enabled insulin delivery system with insulin dose tracking and advice. Expert Opin Drug Deliv. 2017;14(5):697–703. https://doi.org/10.1080/17425247.2017.1313831.CrossRefPubMed

31.

O’Connor MR, Carlin K, Coker T, Zierler B, Pihoker C. Disparities in insulin pump therapy persist in youth with type 1 diabetes despite rising overall pump use rates. J Pediatr Nurs. 2019;44:16–21. https://doi.org/10.1016/j.pedn.2018.10.005.CrossRefPubMed

32.

Puckett C, Wong JC, Daley TC, Cossen K. How organizations shape medical technology allocation: Insulin pumps and pediatric patients with type 1 diabetes. Soc Sci Med. 1982;2020(249):112825. https://doi.org/10.1016/j.socscimed.2020.112825.CrossRef

33.

NCD - Infusion Pumps (280.14). Accessed November 17, 2021. https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=223&ncdver=2

34.

Lee SWH, Chan CKY, Chua SS, Chaiyakunapruk N. Comparative effectiveness of telemedicine strategies on type 2 diabetes management: a systematic review and network meta-analysis. Sci Rep. 2017;7:12680. https://doi.org/10.1038/s41598-017-12987-z.CrossRefPubMedPubMedCentral

35.

Verhoeven F, Tanja-Dijkstra K, Nijland N, Eysenbach G, van Gemert-Pijnen L. Asynchronous and synchronous teleconsultation for diabetes care: a systematic literature review. J Diabetes Sci Technol. 2010;4(3):666–84. https://doi.org/10.1177/193229681000400323.CrossRefPubMedPubMedCentral

36.

Medicare and Medicaid Programs; Policy and regulatory revisions in response to the COVID-19 public health emergency. Federal register. Published April 6, 2020. Accessed November 24, 2021. https://www.federalregister.gov/documents/2020/04/06/2020-06990/medicare-and-medicaid-programs-policy-and-regulatory-revisions-in-response-to-the-covid-19-public

37.

Lu H, Holt JB, Cheng YJ, Zhang X, Onufrak S, Croft JB. Population-based geographic access to endocrinologists in the United States, 2012. BMC Health Serv Res. 2015;15:541. https://doi.org/10.1186/s12913-015-1185-5.CrossRefPubMedPubMedCentral

38.

Su D, Zhou J, Kelley MS, et al. Does telemedicine improve treatment outcomes for diabetes? A meta-analysis of results from 55 randomized controlled trials. Diabetes Res Clin Pract. 2016;116:136–48. https://doi.org/10.1016/j.diabres.2016.04.019.CrossRefPubMed

39.

Isaacs T, Hunt D, Ward D, Rooshenas L, Edwards L. The inclusion of ethnic minority patients and the role of language in telehealth trials for type 2 diabetes: a systematic review. J Med Internet Res. 2016;18(9):e6374. https://doi.org/10.2196/jmir.6374.CrossRef

40.

Myers A, Presswala L, Bissoonauth A, et al. Telemedicine for disparity patients with diabetes: the feasibility of utilizing telehealth in the management of uncontrolled type 2 diabetes in black and Hispanic disparity patients; a pilot study. J Diabetes Sci Technol. 2020;15(5):1034–41. https://doi.org/10.1177/1932296820951784.CrossRefPubMedPubMedCentral

41.

Carter EL, Nunlee-Bland G, Callender C. A patient-centric, provider-assisted diabetes telehealth self-management intervention for urban minorities. Perspect Health Inf Manag AHIMA Am Health Inf Manag Assoc. 2011;8(Winter):1b.

42.

Weinstock RS, Teresi JA, Goland R, et al. Glycemic control and health disparities in older ethnically diverse underserved adults with diabetes: five-year results from the informatics for diabetes education and telemedicine (IDEATel) study. Diabetes Care. 2011;34(2):274–9. https://doi.org/10.2337/dc10-1346.CrossRefPubMedPubMedCentral

43.

Oseran AS, Rao K, Chang Y, et al. HbA1c-triggered endocrinology electronic consultation for type 2 diabetes management. J Gen Intern Med. Published online October 4, 2021. https://doi.org/10.1007/s11606-021-07157-x

44.

Patel PS, Jiang B, Marcelli M, Mediwala SN, Vasudevan MM. Electronic consultation: an effective alternative to in-person clinical care for patients with diabetes mellitus. J Diabetes Sci Technol. 2019;13(1):152–3. https://doi.org/10.1177/1932296818807472.CrossRefPubMed

45.

Heitkemper EM, Mamykina L, Travers J, Smaldone A. Do health information technology self-management interventions improve glycemic control in medically underserved adults with diabetes? A systematic review and meta-analysis. J Am Med Inform Assoc JAMIA. 2017;24(5):1024–35. https://doi.org/10.1093/jamia/ocx025.CrossRefPubMed

46.

Broadband access as a public health issue: the role of Law in expanding broadband access and connecting underserved communities for better health outcomes - Brittney Crock Bauerly, Russell F. McCord, Rachel Hulkower, Dawn Pepin, 2019. Accessed October 12, 2021. https://journals.sagepub.com/doi/https://doi.org/10.1177/1073110519857314

47.

USAC Affordable Connectivity Program. https://www.affordableconnectivity.gov/. Accessed 26 May 2022

48.

Jain V, Al Rifai M, Lee MT, et al. Racial and geographic disparities in internet use in the U.S. Among patients with hypertension or diabetes: implications for telehealth in the Era of COVID-19. Diabetes Care. 2021;44(1):e15–7. https://doi.org/10.2337/dc20-2016.CrossRefPubMed

49.

George S, Hamilton A, Baker RS. How Do Low-income urban African Americans and Latinos feel about telemedicine? a diffusion of innovation analysis. Int J Telemed Appl. 2012;2012:715194. https://doi.org/10.1155/2012/715194.CrossRefPubMedPubMedCentral

50.

Rodriguez JA, Saadi A, Schwamm LH, Bates DW, Samal L. Disparities in telehealth use among California patients with limited English proficiency. Health Aff Proj Hope. 2021;40(3):487–95. https://doi.org/10.1377/hlthaff.2020.00823.CrossRef

51.

Haynes SC, Kompala T, Neinstein A, Rosenthal J, Crossen S. Disparities in telemedicine use for subspecialty diabetes care during COVID-19 shelter-in-place orders. J Diabetes Sci Technol. 2021;15(5):986–92. https://doi.org/10.1177/1932296821997851.CrossRefPubMedPubMedCentral

Titel: The Use of Diabetes Technology to Address Inequity in Health Outcomes: Limitations and Opportunities
verfasst von: Shivani Agarwal
Iman Simmonds
Alyson K. Myers
Publikationsdatum: 01.06.2022
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 7/2022
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-022-01470-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

RAS-Blocker bei Hyperkaliämie möglichst nicht sofort absetzen

14.05.2024 Hyperkaliämie Nachrichten

Bei ausgeprägter Nierenfunktionsstörung steigen unter der Einnahme von Renin-Angiotensin-System(RAS)-Hemmstoffen nicht selten die Serumkaliumspiegel. Was in diesem Fall zu tun ist, erklärte Prof. Jürgen Floege beim diesjährigen Allgemeinmedizin-Update-Seminar.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Bildnachweise

Die Leitlinien für Ärztinnen und Ärzte, Ärztin führt eine Nierenultraschalluntersuchung durch/© Graphicroyalty / stock.adobe.com (Symbolbild mit Fotomodell), Schwangere misst Blutzucker/© MMPhotography / Getty Images / iStock (Symbolbild mit Fotomodell), Duktales Pankreaskarzinom/© Dörffel, Y., Wermke, W. / all rights reserved Springer Medizin Verlag GmbH, Füße einer adipösen Frau auf einem Laufband/© Idanupong / stock.adobe.com (Symbolbild mit Fotomodell)

Springer Medizin

Abstract

Purpose of Review

Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2022

The Clash of Two Epidemics: the Relationship Between Opioids and Glucose Metabolism

SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis

Barriers and Facilitators to Diabetes Device Adoption for People with Type 1 Diabetes

Friend or Foe: a Narrative Review of the Impact of Diabetes Technology on Sleep